% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Cardoso:180668,
      author       = {R. Cardoso$^*$ and F. Guo$^*$ and T. Heisser$^*$ and H. De
                      Schutter and N. Van Damme and M. C. Nilbert and J.
                      Christensen and A.-M. Bouvier and V. Bouvier and G. Launoy
                      and A.-S. Woronoff and M. Cariou and M. Robaszkiewicz and P.
                      Delafosse and F. Poncet and P. M. Walsh and C. Senore and S.
                      Rosso and V. E. P. P. Lemmens and M. A. G. Elferink and S.
                      Tomšič and T. Žagar and A. L. d. M. Marques and R.
                      Marcos-Gragera and M. Puigdemont and J. Galceran and M.
                      Carulla and A. Sánchez-Gil and M.-D. Chirlaque and M.
                      Hoffmeister$^*$ and H. Brenner$^*$},
      title        = {{O}verall and stage-specific survival of patients with
                      screen-detected colorectal cancer in {E}uropean countries:
                      {A} population-based study in 9 countries.},
      journal      = {The lancet / Regional health. Europe},
      volume       = {21},
      issn         = {2666-7762},
      address      = {[Amsterdam]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2022-01468},
      pages        = {100458},
      year         = {2022},
      note         = {#EA:C120#LA:C120#LA:C070#},
      abstract     = {An increasing proportion of colorectal cancers (CRCs) are
                      detected through screening due to the availability of
                      organised population-based programmes. We aimed to analyse
                      survival probabilities of patients with screen-detected CRC
                      in European countries.Data from CRC patients were obtained
                      from 16 population-based cancer registries in nine European
                      countries. We included patients with cancer diagnosed from
                      the year organised CRC screening programmes were introduced
                      until the most recent year with available data at the time
                      of analysis, whose ages at diagnosis fell into the age
                      groups targeted by screening. Patients were followed up with
                      regards to vital status until 2016-2020 across the various
                      countries. Overall and CRC-specific survival were analysed
                      by mode of detection and stage at diagnosis for all
                      countries combined and for each country separately using the
                      Kaplan-Meier method.We included data from 228 134 patients,
                      of whom 134 597 (aged 60-69 years at diagnosis targeted by
                      screening in all countries) were considered in analyses for
                      all countries combined. $22·3\%$ (38 080/134 597) of
                      patients had cancer detected through screening. Most
                      screen-detected cancers were found at stages I-II $(65·6\%$
                      [12 772/19 469 included in stage-specific analyses]), while
                      the majority of non-screen-detected cancers were found at
                      stages III-IV $(56·4\%$ [31 882/56 543 included in
                      stage-specific analyses]). Five-year overall and
                      CRC-specific survival rates for patients with
                      screen-detected cancer were $83·4\%$ $(95\%$ CI
                      82·9-83·9) and $89·2\%$ (88·8-89·7), respectively; for
                      patients with non-screen-detected cancer, they were much
                      lower $(57·5\%$ [57·2-57·8] and $65·7\%$ [65·4-66·1],
                      respectively). The favourable survival of patients with
                      screen-detected cancer was also seen within each stage -
                      five-year overall survival rates for patients with
                      screen-detected stage I, II, III, and IV cancers were
                      $92.4\%$ $(95\%$ CI 91·6-93·1), $87·9\%$ (86·6-89·1),
                      $80·7\%$ (79·3-82·0), and 32·3 (29·4-35·2),
                      respectively. These patterns were also consistently seen for
                      each individual country.Patients with cancer diagnosed at
                      screening have a very favourable prognosis. In the rare case
                      of detection of advanced stage cancer, survival
                      probabilities are still much higher than those commonly
                      reported for all patients regardless of mode of detection.
                      Although these results cannot be taken to quantify screening
                      effects, they provide useful and encouraging information for
                      patients with screen-detected CRC and their physicians.This
                      study was supported in part by grants from the German
                      Federal Ministry of Education and Research and the German
                      Cancer Aid.},
      keywords     = {Colorectal cancer (Other) / Europe (Other) / Screening
                      (Other) / Survival (Other)},
      cin          = {C120 / C070 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C120-20160331 / I:(DE-He78)C070-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35832063},
      pmc          = {pmc:PMC9272368},
      doi          = {10.1016/j.lanepe.2022.100458},
      url          = {https://inrepo02.dkfz.de/record/180668},
}